Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 3/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492260 | 0.90 | SLC2A1 (0.41) | SLC2A1COMTSLC11A2TNKSTNKS2 | |
| SCHEMBL4565033 | 0.84 | SLC2A1 (0.43) | SLC2A1COMTSLC11A2TNKSTNKS2 | |
| SCHEMBL4483751 | 0.78 | PTGES (0.48) | SLC2A1COMTSLC11A2 | |
| SCHEMBL4480629 | 0.78 | DAO (0.44) | SLC2A1COMTSLC11A2RAB9ADAO | |
| SCHEMBL4490726 | 0.78 | SLC2A1 (0.61) | SLC2A1DAO | |
| SCHEMBL9268964 | 0.77 | SLC2A1 (0.58) | SLC2A1SLC11A2TNKSKIF11DAO | |
| SCHEMBL4472769 | 0.76 | KDM1A (0.45) | SLC2A1 | |
| SCHEMBL4491220 | 0.76 | SLC2A1 (0.43) | SLC2A1 | |
| SCHEMBL4485644 | 0.75 | FEN1 (0.44) | SLC2A1 | |
| SCHEMBL4486314 | 0.75 | SLC2A1 (0.43) | SLC2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | claimed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | claimed |
| EP-1858876-A2 | PYRIDINONE DERIVATIVES AGAINST MALARIA | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | claimed |
| WO-2006094799-A2 | PYRIDINONE DERIVATIVES AGAINST MALARIA | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | claimed |
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | G6PD, PNPO, PLPBP | SLC2A1 2278/4885COMT 2974/4885SLC11A2 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.